bea

Beactica Therapeutics is a Swedish precision medicine company focused on developing novel small-molecule therapeutics for genetically defined cancers with high unmet medical needs. The company utilizes its proprietary Eclipsor platform to identify and develop allosteric modulators and targeted protein degraders, specifically targeting synthetically lethal disease proteins. Its lead program, BEA-17, is a first-in-class small-molecule degrader of the LSD1–CoREST protein complex, which has received Orphan Drug Designation from the FDA for the treatment of glioblastoma. Beactica aims to advance its programs to clinical proof-of-concept, often through strategic collaborations with academic and industry partners.